| Name |
Functions |
| Prostate Specific Antigen (PSA) |
Used as detection marker for prostate cancer.
Tried in multiple immunotherapy vaccines.
HLA class II epitopes have been identified in mouse models. |
| Prostatic Acid Phosphatase (PAP, PAcP) |
Predates PSA as screening marker, particularly in cases of bone metastasis.
HLA class II epitopes have been identified.
Used as fusion protein with GM-CSF in Provenge DC therapy. |
| Prostate Specific Membrane Antigen (PSMA) |
Membrane bound protein with increased expression in prostate cancer. Used as target for in vivo imaging and therapy techniques using monoclonal antibodies.
HLA class II immunodominant epitope identified. |
| Telomerase (TERT, hTERT) |
Increases telomere length leading to tumor progression and unchecked cell division.
TERT protein has been identified as immunoreactive in TRAMP mouse model of prostate cancer.
No HLA class II epitopes identified at this point. |
| Survivin (SVN, SUR) |
Inhibitor of apoptosis in prostate cancer leading to increased cell division. HLA class II epitopes have been identified.
Subject of multiple ongoing immunotherapy vaccine strategies. |
| Prostate Stem Cell Antigen (PSCA) |
Cell-surface, glycosylphosphatidylinositol-anchored protein expressed in prostate cancer.
PSCA is a target for peptide and antibody based therapy.
No HLA class II epitopes identified at this point. |
